autologous IKDC-like cells

Autologous IKDC-like cells refer to a cell therapy product composed of immune cells with characteristics similar to innate lymphoid killer dendritic cells (IKDCs), derived from and administered back to the same individual. These are a subset of immune effector cells that display both natural killer (NK) cell and dendritic cell features, potentially offering cytotoxic activity against tumor or infected cells as well as antigen-presenting capabilities. The mechanism of action is believed to involve direct cytotoxicity against target (e.g., cancer) cells and modulation or activation of adaptive immune responses through antigen presentation. This approach falls under the broader category of adoptive cellular immunotherapy, where patient-derived immune effector populations are expanded or modified ex vivo before reinfusion for therapeutic purposes[1][2][7]. The primary indications under investigation for such therapies include various cancers, though specific clinical trial data on "autologous IKDC-like cells" as a distinct product is limited.